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Abstract
Background: Treatment for chronic hepatitis B (CHB) is virtually absent in sub-Saharan Africa. Here we present early
experiences from a pilot program for treatment of CHB in Ethiopia.
Methods: Adults (≥18 years) with CHB were included in a cohort study at St. Paul’s Hospital Millennium Medical
College, Addis Ababa, from February 2015. The baseline assessment included liver function tests, viral markers and
transient elastography (Fibroscan 402, Echosense, France). Logistic regression models were used to identify predictors
of fibrosis. Tenofovir disoproxil fumarate (TDF) was initiated based on the European Association for the Study of the
Liver (EASL) criteria, with some modifications. The initial 300 patients underwent a more comprehensive evaluation and
are presented here.
Results: One-hundred-and-thirty-eight patients (46.0%) were women and median age was 30 years (interquartile range
26–40). Co-infections were rare: four patients (1.3%) were anti-HCV positive, 11 (3.7%) were anti-HDV positive, whereas
5 (1.7%) had HIV-infection. The majority were hepatitis B e-antigen (HBeAg) negative (n = 262; 90.7%) and had a normal
(≤40 U/L) alanine aminotransferase (ALT) (n = 245; 83.1%). Of 268 patients with a valid Fibroscan result, 79 (29.5%) had
significant fibrosis (>7.9 kPa). Independent predictors of fibrosis were male sex, age > 35 years and viral load >20,000 IU/ml.
In total, 74 patients (24.7%) started TDF therapy, of whom 46 (62.2%) had cirrhosis.
Conclusions: The majority were HBeAg negative and had normal ALT. However, one quarter of the patients were in need
of antiviral treatment, underscoring the need to scale up CHB treatment on the African continent.
Trial registration: NCT02344498 (ClinicalTrials.gov identifier). Registered 16 January 2015.
Keywords: Hepatitis B virus, Antiviral therapy, Resource-limited settings, Africa
Background
One third of the world’s population have serological evi-
dence of past or present infection with hepatitis B virus
(HBV), while 240 million people are chronic hepatitis B
surface antigen (HBsAg) carriers. There are wide geo-
graphical variations, with the highest prevalence found
in East Asia and Sub-Saharan Africa. Chronic hepatitis B
(CHB) has a variable natural history, ranging from an
inactive carrier state with an excellent long-term prog-
nosis, to progressive liver fibrosis which may lead to the
development of cirrhosis and hepatocellular carcinoma
(HCC). Of adults with CHB, approximately 20–30% will
develop these complications, and an estimated 686,000
people die prematurely due to HBV every year. The natural
course depends on several factors, such as HBV viral load
and genotype, co-infection with other viruses including
hepatitis C virus (HCV), hepatitis D virus (HDV) or human
immunodeficiency virus (HIV), and other host factors such
as alcohol abuse and obesity [1–3].
Antiviral agents active against HBV have been shown
to suppress HBV replication, prevent progression to cir-
rhosis, and reduce the risk of HCC and liver-related
death [4–6]. International liver societies have issued
guidelines for the treatment of CHB [2, 7], and a number
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of studies have demonstrated the safety and efficacy of
antiviral treatment of HBV in high-income countries
[4, 5, 8, 9]. These experiences, however, are not necessarily
translatable to an African setting, where epidemiological,
environmental and socioeconomic factors are different,
which in turn might impact the natural history, disease pro-
gression and risk of cirrhosis and HCC [10].
In 2015, the World Health Organization (WHO) issued
guidelines for the prevention, care and treatment for persons
with CHB, with an emphasis on resource-limited settings
[1], but still little is known about treatment indications
and outcomes in sub-Saharan Africa. Only a few African
countries have developed national treatment plans for
CHB, and although tenofovir disoproxil fumarate (TDF) is
widely available in HIV programs throughout the continent,
access to antiviral therapy for CHB mono-infected individ-
uals is severely restricted. In 2016, the WHO launched the
Global Health Sector Strategy of Viral Hepatitis, with
the aim of reducing deaths due to viral hepatitis by 65%
within 2030 [3]; however, achieving this aim will require
concerted action from both international stakeholders and
the countries affected. Currently, only 9% of HBV-infected
individuals have been tested, and of those diagnosed only
8% were on treatment in 2015 [11]. Hence, it is imperative
to improve access to hepatitis B treatment in Africa, and
real-life experiences from African treatment cohorts are
urgently needed to direct implementation, policy change
and local treatment guidelines.
Ethiopia is one of the most populous nations in Africa
with a population size of close to 100 million. The esti-
mated life expectancy is 65 years, and the major health
problems of the country are preventable communicable
diseases [12]. The sero-prevalence of HBsAg is estimated
to be 7.4%, and more than 60% of chronic liver disease
and up to 80% of HCC are due to hepatitis B and C
infections [13]. Although HBsAg screening is widely
available in the country, access to CHB treatment has
been absent up to now, except through the “black market”.
In 2015, we set up a pilot program for treatment and care of
CHB in Ethiopia, using a simplified protocol, aiming to
evaluate the implementation of modern antiviral treatment
in a resource-limited setting. For scientific purposes, the ini-
tial 300 patients underwent comprehensive characterization
at inclusion. Early experiences from the program are pre-
sented here.
Methods
Study setting and participants
A treatment program was established in February 2015
at St. Paul’s Hospital Millennium Medical College, which
is located in the capital city Addis Ababa. It is a tertiary
hospital delivering medical services to patients referred
from all over the country. This was the first center offering
CHB treatment in the country, and health care providers
at other hospitals and clinics were informed about the
new services provided. Hence, HBsAg positive individuals
were referred both from hospital departments based on
clinical liver disease, and from blood banks and antenatal
care clinics based on a positive screening test.
Consenting adults (≥18 years of age) with CHB were
eligible for enrolment in the cohort study, in the absence
of HCC and other terminal illnesses. CHB was defined
as a persistent positive HBsAg for more than 6 months
[1]. In patients without a previous HBsAg test, or if the
first positive HBsAg test was less than 6 months ago,
HBsAg testing was repeated in order to distinguish from
acute hepatitis B. Patients with HIV co-infection were
transferred to the nearest HIV care and treatment center.
Although this CHB treatment center was set up as a
research program with external funding, the long-term
sustainability will be ensured through the National Hepatitis
Program. The Ethiopian Ministry of Health, as one of the
first in sub-Saharan Africa, recently issued national
guidelines for the prevention and control of viral hepatitis
[14], and since 2016, antiviral therapy has been available
to patients with CHB at selected hospitals and clinics in
the country.
Ethical clearance was obtained from the Regional Com-
mittee for Medical and Health Research Ethics in Norway
and the National Research Ethics Review Committee in
Ethiopia, as well as the pertinent institutional ethical review
boards. Written informed consent was obtained from all
study participants.
Data collection
All patients were interviewed and examined using a stan-
dardized form. Baseline data included sociodemographic
information, pregnancy/breastfeeding status, and previous
use of antiviral agents and other medications. Past medical
history included previous liver diseases, previous hepatitis
serology, and ingestion of alcohol, khat (a psychostimulant
plant native to the Horn of Africa and the Arabian
peninsula) and other substances. Harmful alcohol use
was defined as more than 30 g/day for men and 20 g/day
for women [15], and khat abuse was defined as current
use of khat, regardless of the quantity. Physical examin-
ation included liver stigmata, such as spider angiomas,
jaundice and ascites.
Laboratory analyses
Blood samples were collected at inclusion and thereafter
3-monthly, and tested locally for hematology, biochemistry
and standard serology. HBsAg was detected using a WHO
approved rapid diagnostic test (Determine, Alere Inc., USA).
Routine laboratory investigations were carried out using the
following kits and assays: hematology (HumaCount 30,
Human, Germany), biochemistry (Humalyzer 3000, Human,
Germany), and serology (Elisys Uno, Human, Germany).
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HIV-testing was done in accordance with the National
algorithm, i.e. using a WHO approved rapid test kit
(HIV 1 + 2 Antibody Colloidal Gold [KHB], Shanghai
Kehua Bio-engineering co., China) for screening, and
another rapid test kit (HIV 1/2 STAT-PAK, Chembio
Diagnostics, USA) for confirmation.
Testing for hepatitis B e-antigen (HBeAg), anti-HBe,
HBV DNA viral load, HBV genotyping and hepatitis delta
virus (HDV) was performed at the Norwegian Public Health
Institute (Oslo, Norway). HBeAg/anti-HBe were analyzed
using an enzyme-linked fluorescent immunoassay (VIDAS
HBe/anti-HBe, BioMérieux, Marcy l’Etoile, France). HDV
antibodies were detected using an enzyme-linked immuno-
sorbent assay (ETI-AB-DELTAK-2, Diasorin, Italy).
The Abbott RealTime HBV assay (Abbott Molecular,
Des Moines, USA) was used for viral load testing, following
the manufacturer’s instructions. For genotyping an in-house
sequence based assay was used. After extraction with the
Abbot sp2000 system (Abbott Molecular, Des Moines,
USA), HBV DNA was amplified using HBV-specific primers
covering the small S-gene region 5′– GACCCCTGCTC
GTGTTA −3` (forwards) and 5′– TGAATACTTTCCAAT
CAATAGG – 3′ (reverse). The applied PCR conditions
were AB-gene PCR-buffer with Syber green (0.33×), Pt-Taq,
3 mMMg, 0.5 uM primer, 0.2 mM dNTP. The thermal cyc-
ling conditions were: denaturation, 95 °C for 2 min; amplifi-
cation, 45 cycles of 15 s at 95 °C, 45 s at 65 °C, 90 s at 72 °C.
The PCR products (797 bp) were further sequenced using
Big Dye Terminator v3.1 on the ABI Prism 3100 instrument
(Applied Biosystems, Foster City, USA). Sequencing condi-
tions were: 25 cycles at 96 °C for 15 s followed by annealing
and elongation at 60 °C for 4 min. The HBV genotype was
determined using the genotyping databases (www.geno2
pheno.org) at the Max-Planck-Institute for informatics
(http://hbv.bioinf.mpi-inf.mpg.de).
Assessment of liver fibrosis
Liver fibrosis was assessed using transient elastography
(Fibroscan 402, Echosense, France) and was part of the
baseline examination in all patients. Patients were instructed
to fast for at least 2 h prior to the examination, and the pro-
cedure was performed by a trained, experienced operator as
per the manufacturer’s instructions. The median of 10 read-
ings was employed, and the result was discarded if the inter-
quartile range (IQR) divided by the median exceeded 30%.
A Fibroscan threshold of 7.9 kPa was used to define
significant fibrosis (Metavir score ≥ F2), based on a
meta-analysis of Asian and European patients [16] and a
recent study from West Africa [17]. To define cirrhosis
(Metavir score F4), the West African study identified
9.5 kPa as the optimal threshold, which is lower than most
other studies. We decided to use a Fibroscan threshold of
9.9 kPa to define cirrhosis, both for simplicity (“10 kPa and
above is cirrhosis”) and to improve specificity. In patients
with grossly elevated ALT (a “flare”), Fibroscan measure-
ments were repeated over a period of at least 3 months,
since liver stiffness can be overestimated in this situation
[18]. Ultrasound of the liver was performed in patients who
started antiviral treatment, mainly to exclude HCC.
Treatment eligibility
The present treatment program in Ethiopia was established
prior to the release of the WHO guidelines for CHB treat-
ment; hence, we based treatment eligibility criteria in our
program on the European Association for the Study of the
Liver (EASL) guidelines from 2012, which recommend
treatment in the following situations: a) significant fibrosis
and viral load >2000 IU/mL, or b) moderate/severe
necroinflammation (Metavir score ≥ A2 on liver biopsy)
and viral load >2000 IU/mL, or c) alanine aminotransferase
(ALT) >80 U/L and viral load >20,000 IU/mL, or d) cirrho-
sis and any detectable viral load [2]. Some modifications of
the EASL criteria were required to fit a low-income setting;
specifically, since liver biopsy was unavailable in our setup,
we merged criteria b and c into a new one: ALT >80 U/L
and viral load >2000 IU/mL. Furthermore, since Africans
with CHB are at particular risk of HCC [1], we added a cri-
terion about HCC in near family.
Thus, patients who fulfilled the following criteria were
considered eligible for treatment in the present program:
a) Decompensated cirrhosis
b) Compensated cirrhosis (confirmed with ultrasound
or Fibroscan)
c) ALT >80 U/L (i.e. 2 times the upper limit of normal)
and viral load >2000 IU/mL
d) Fibroscan >7.9 kPa and viral load >2000 IU/mL
e) HCC among first-grade relative and viral load
>2000 IU/mL
Patients who were eligible for treatment were given
adherence counseling before starting antiviral treatment.
Based on its potency, low risk of resistance, safety profile
and favorable costs, TDF (Viread, Gilead Sciences Inc.,
USA) 300 mg once daily was the drug used in the
current study.
In a separate analysis, we compared the treatment
eligibility criteria employed in the present program
(“St. Paul criteria”) with those of the EASL guidelines
from 2012 and 2017 and the WHO guidelines from
2015. Treatment experienced patients were excluded
from this analysis since the basis for treatment eligibility
assessment (mainly ALT and viral load) could be affected
by ongoing therapy. The EASL 2017 criteria were the
same as the EASL 2012 criteria (a to d) described above,
with the addition of: e) HBeAg positive patients older than
30 years of age, and f) a family history of HCC or cirrhosis
[19]. The WHO criteria were: a) clinically diagnosed
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cirrhosis, or b) aspartate aminotransferase to platelet ratio
index (APRI) >2.0, or c) age ≥ 30 years with abnormal
ALT and viral load >20,000 IU/mL [1].
Statistical analysis
Descriptive statistics were used to summarize patient
demographics and other baseline characteristics. Logistic
regression models were used to study associations between
baseline variables and the presence of significant liver fibro-
sis, defined as a Fibroscan value above 7.9 kPa [16]. Six
patients with ALT level above 200 U/L (i.e. more than 5
times the upper limit of normal) were excluded from this
analysis since ALT elevation can cause falsely elevated
Fibroscan results [18]. Univariable logistic regression was
computed for the following variables: age, gender, alcohol
abuse, HBeAg, HBV genotype, HDV co-infection, ALT level
and HBV viral load. Variables with a p-value below 0.1 in
univariable analyses were included in the multivariable lo-
gistic regression model, using a forward stepwise method.
Multi-collinearity was excluded using Spearman’s correl-
ation coefficient with a cutoff at 0.7. All tests were two-
sided and the significance level was set at P < 0.05. Data
were analyzed using SPSS for Windows version 23.0 (SPSS
Inc., Chicago, USA).
Results
Baseline characteristics
Among the initial 300 patients, 138 (46.0%) were women,
of whom 19 (13.7%) were pregnant and 16 (12.0%) were
breastfeeding. The median age of the study participants was
30 years (interquartile range [IQR] 26–40). Co-infections
were relatively rare: 5 patients (1.7%) had HIV-infection
and were referred to HIV care, 4 patients (1.3%) had hepa-
titis C co-infection, and 11 patients (3.7%) were anti-HDV
positive. Alcohol abuse was reported in 5 patients (1.7%)
and khat abuse in 18 (6.0%). Baseline characteristics of the
study participants are summarized in Table 1.
Twenty-nine patients (9.7%) reported previous exposure
to antiviral treatment, either through the private sector or
from the “black market”. The antiviral regimens reported
by these patients were: TDF (n = 15), TDF/lamivudine
fixed-dose combination (n = 7), lamivudine (n = 3), and
pegylated interferon (n = 4). By the time of enrolment in
the study, 17 were still taking their antiviral drugs, of whom
11 had a completely suppressed viral load (<15 IU/ml). The
remaining had quit either for financial reasons or because
they could no longer access the drugs or because they had
completed the prescribed course of pegylated interferon.
The majority of patients were HBeAg negative (n = 262;
90.7%) and had a low viral load: median viral load was
1129 IU/ml (IQR 191–12,861). Similarly, most patients
had a normal ALT: median ALT was 23 U/L (IQR 16–33).
HBV genotyping was performed in 79 patients, and only
genotypes A and D were identified.
Table 1 Baseline characteristics of 300 patients with chronic
hepatitis B, Addis Ababa, Ethiopia
Characteristics Number (%)
Sex
Male 162 (54.0)
Female 138 (46.0)
Age group (years)
18–25 65 (21.7)
26–35 129 (43.0)
36–45 60 (20.0)
> 45 46 (15.3)
Marital status
Single 104 (34.7)
Married 185 (61.7)
Divorced/widowed 11 (3.6)
Previous antiviral treatment
Yes 29 (9.7)
No 271 (90.3)
Substance abuse
Alcohol 5 (1.7)
Khat 18 (6.0)
Fasting TE value (kPa) (n = 268)
≤ 7.9 189 (70.5)
8.0–9.9 29 (10.8)
> 9.9 50 (18.7)
ALT (U/L) (n = 295)
≤ 40 245 (83.1)
41–80 34 (11.5)
> 80 16 (5.4)
HBeAg (n = 289)
Positive 27 (9.3)
Negative 262 (90.7)
HBV viral load (IU/ml) (n = 294)
< 2000 169 (57.5)
2000–20,000 60 (20.4)
≥ 20,000 65 (22.1)
HBV genotype (n = 79)
A 67 (84.8)
D 12 (15.2)
Co-infections
HIV 5 (1.7)
HCV 4 (1.3)
HDV (n = 294) 11 (3.7)
TE transient elastography, ALT alanine aminotransferase, HBeAg hepatitis B
e-antigen, HBV hepatitis B virus, HIV human immunodeficiency virus, HCV
hepatitis C virus, HDV hepatitis D virus
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Transient elastography was successful in 268 patients,
and the median Fibroscan value was 5.8 kPa (IQR 4.8–
8.0). Thirty-two patients (10.7%) did not have a valid
Fibroscan result; the main reasons for an invalid or miss-
ing result were pregnancy (elastography contraindicated,
n = 14), ascites (elastography not feasible, n = 7) and
overweight/obesity (body mass index >25 kg/m2; n = 7).
Antiviral treatment
Out of all 300 patients in this analysis, 74 (24.7%) met
the treatment eligibility criteria and started treatment,
the majority of whom (n = 46; 62.2%) had cirrhosis. Four
patients with cirrhosis did not start treatment; one died
shortly after enrolment, one refused treatment, and two
had advanced HCC at ultrasonography and were transferred
to palliative care. At the other end of the scale, 103 of 265
patients (38.9%) with a complete laboratory profile at base-
line, had entirely normal findings (Fibroscan ≤7.9 kPa, viral
load <2000 IU/ml, ALT ≤40 U/L), suggesting that they were
inactive carriers.
The various treatment guidelines were compared in a
subset of 271 treatment naïve patients. As expected, there
was a good concordance between the St. Paul criteria and
the EASL 2012 criteria (Table 2). The EASL 2017 guide-
lines introduced two new eligibility criteria; hence, the
number of eligible patients was higher compared to the
previous version. Of concern, using the WHO 2015 guide-
lines, only 29 patients (10.7%) were eligible for treatment,
most of whom had decompensated cirrhosis.
Factors associated with liver fibrosis
Seventy-nine patients had significant liver fibrosis (Fibros-
can >7.9 kPa) at baseline. Figure 1 illustrates the degree of
fibrosis as a function of age, sex, ALT and viral load level.
Logistic regression analysis, after exclusion of six
patients with a grossly elevated ALT, showed that male
sex, increasing age, HBeAg positivity, ALT >40 U/L
and viral load >20,000 IU/ml were significantly associated
with liver fibrosis in univariable analysis. In the multivari-
able logistic regression model, only sex, age and viral load
remained significant (Table 3).
Discussion
In this study, we describe the initial 300 patients who
took part in one of the first and largest treatment programs
for CHB in sub-Saharan Africa. Of concern, even though
most of the patients were below 40 years of age, many had
advanced liver disease at enrolment. Nearly one third had
significant liver fibrosis, of whom the majority had cirrhosis.
Based on our modified EASL treatment criteria, about one
quarter of the patients were in need of antiviral treatment.
Since this was the first public sector treatment program in
Ethiopia, it is unsurprising that symptomatic patients,
desperate for lifesaving medicines, were overrepresented in
the early phase. In fact, this resembles the situation in HIV
care a decade ago, when new treatment programs were
often overwhelmed with patients with advanced disease
[20]. This underscores the need to scale up CHB treatment
in the country, and make antiviral therapy available to those
in need.
Fig. 1 Liver fibrosis as a function of a sex, b age, c ALT and d HBV viral load in a cohort of patients with chronic hepatitis B in Ethiopia. Patients
with invalid/missing Fibroscan results or ALT elevated more than 5 times the upper limit of normal were excluded from this analysis
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The vast majority of patients in our cohort were HBeAg
negative. This is in line with previous studies indicating
that African CHB patients have a lower rate of HBeAg
positivity compared to those in the Far East [21]. This
phenomenon is explained, at least partly, by geographical
variations in HBV genotypes and mode of transmission
[22]. Indeed, over the past few decades, HBeAg negative
CHB has become the commonest type of HBV infection
in many countries of the world. Patients with HBeAg
negative CHB have exacerbations with high viral load, ele-
vated ALT and histologic activity, and have been shown to
develop cirrhosis faster than patients with HBeAg positive
CHB [23]. Timely antiviral therapy is particularly benefi-
cial in this patient group, as studies have shown that sup-
pression of HBV not only stops the progression of liver
disease, but also leads to regression of liver fibrosis and
cirrhosis [5, 24]. Furthermore, up to 8 years of treatment
with TDF has been shown to be effective, safe and without
development of resistance [25].
Approximately one third of our cohort had low viral
replication and no evidence of liver disease, and were
assumed to be “inactive carriers”. Such patients have an
excellent long-term prognosis even in the absence of
treatment [26, 27]. In low-income settings, it seems reason-
able to focus resources on patients who can be expected to
benefit the most from follow-up and treatment. Hence, in
an Ethiopian context, we decided that inactive carriers
could be discharged from the program after a period of
one year, provided that they had repeatedly normal
laboratory tests. Certainly, the reduced personnel and
laboratory costs in these patients must be balanced
against the small risk of reactivation of HBV [28]. The
Table 3 Baseline variables associated with significant fibrosis (Fibroscan >7.9 kPa) among Ethiopian patients with chronic hepatitis B
(n = 260)
No fibrosis N (%) Significant fibrosis N (%) Crude Adjusted
Baseline variable OR (95% CI) P OR (95% CI) P
Gender
Female 99 (53.2) 17 (23.0) 1 1
Male 87 (46.8) 57 (77.0) 3.8 (2.1–7.0) <0.001 3.0 (1.5–5.9) 0.002
Age group (years)
18–25 41 (22.0) 12 (16.2) 1 1
26–35 92 (49.5) 23 (31.1) 0.9 (0.4–1.9) 0.695 1.5 (0.6–3.9) 0.406
36–45 30 (16.1) 22 (29.7) 2.5 (1.1–5.8) 0.033 4.4 (1.5–12.8) 0.006
> 45 23 (12.4) 17 (23.0) 2.5 (1.0–6.2) 0.043 3.6 (1.2–11.0) 0.022
Alcohol abuse
No 184 (98.9) 71 (95.9) 1
Yes 2 (1.1) 3 (4.1) 3.9 (0.6–23.8) 0.142
HBeAg (n = 255)
Negative 174 (95.1) 60 (83.3) 1 1
Positive 9 (4.9) 12 (16.7) 3.9 (1.6–9.6) 0.004 2.7 (0.9–8.4) 0.087
HBV genotype (n = 68)
A 38 (82.6) 19 (86.4) 1
D 8 (17.4) 3 (13.6) 0.8 (0.2–3.2) 0.695
HDV co-infection (n = 259)
No 180 (97.3) 72 (97.3) 1
Yes 5 (2.7) 2 (2.7) 1.0 (0.2–5.3) 1.000
ALT (U/L)
≤ 40 166 (89.2) 56 (75.7) 1 1
> 40 20 (10.8) 18 (24.3) 2.7 (1.3–5.4) 0.006 1.8 (0.8–4.0) 0.162
HBV viral load (IU/ml) (n = 259)
< 2000 114 (61.6) 37 (50.0) 1 1
2000–19,999 47 (25.4) 9 (12.2) 0.6 (0.3–1.3) 0.198 0.7 (0.3–1.6) 0.350
≥ 20,000 24 (13.0) 28 (37.8) 3.6 (1.9–7.0) <0.001 3.2 (1.4–7.4) 0.006
OR odds ratio, CI confidence interval, HBeAg hepatitis B e-antigen, HBV hepatitis B virus, HDV hepatitis D virus, ALT alanine aminotransferase
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cost-effectiveness of this strategy should be investigated
in future studies.
Interestingly, our study revealed a low proportion of
co-infections with HIV (1.7%), HCV (1.3%) and HDV
(3.7%). Several studies from HIV cohorts have reported
much higher co-infection rates. A recent review article
reported HIV/HBV co-infection in the range 5.0–8.3% in
East Africa and 2.7–35.7% in West Africa [29]. However,
the only previous study to report HIV/HBV co-infection
in an African HBV cohort found a relatively low preva-
lence of HIV (3.3%) among HBsAg positive individuals in
The Gambia [30], in keeping with our findings. Although
HIV and HBV share the same transmission routes, most
adults with CHB have been infected in early childhood
and would not have any increased risk of acquiring HIV
later in life [31]. The low HIV prevalence in our CHB
cohort, therefore, is mirroring the HIV prevalence in the
general population in Ethiopia, which is estimated to be
1.2% [12]. Similarly, the low proportion with HBV/HCV
co-infection in our study is probably a reflection of the
overall low prevalence of HCV in Ethiopia [32]. The
presence of anti-HDV antibodies in our study was also
relatively low, which is in line with a previous study
from East Africa; however, available data from the region
is scarce [33].
Male sex, age above 35 years and HBV viral load above
20,000 IU/ml were strong and significant predictors of
advanced liver disease in our cohort. The association
with sex and age observed in our study is similar to
reports from elsewhere [34]. Increasing age is thought to
be a proxy indicator of longstanding HBV infection, whereas
the association between male sex and fibrosis, although
consistently reported throughout the world, is less in-
tuitive. High HBV DNA level was shown to be a strong
risk factor for development of cirrhosis in the REVEAL
study in Taiwan [26], in line with our study. There was
no significant association between fibrosis and alcohol
abuse, HBeAg status, HDV co-infection, ALT level or
genotype in our cohort. In a recent longitudinal study
from The Gambia, male sex, maternal HBsAg status, geno-
type A (compared to E), aflatoxin exposure, HBeAg status,
HBV viral load and ALT level were independent predictors
of development of fibrosis [35]. Local data from Africa are
important to inform evidence-based guidelines, and the
present study is one of few to report predictors of liver
fibrosis in CHB mono-infected patients on the continent.
Our study had certain limitations. First, we used Fibroscan
for staging of liver fibrosis, and since the threshold to iden-
tify cirrhosis (9.9 kPa) was lower than in many other studies,
it is possible that we overestimated the prevalence of cirrho-
sis. However, in the largest study on the African continent a
Fibroscan threshold of 9.5 kPa yielded a sensitivity of 100%
and specificity of 89% [17]. Second, predictors of fibrosis
were investigated using a cross-sectional design, and thus
the direction of any association cannot be ascertained. On
the other hand, the risk factors identified in our study were
well in line with studies from elsewhere, and we believe the
results are valid.
Conclusion
In summary, among the initial 300 patients in one of the
first and largest CHB treatment programs in sub-Saharan
Africa, almost one third had significant liver fibrosis at en-
rolment. Male sex, age above 35 years and viral load above
20,000 IU/ml were strong and significant predictors of
liver fibrosis. Although the vast majority were HBeAg
negative and had normal ALT, approximately one quarter
of the patients were in need of antiviral treatment, most of
whom had cirrhosis. Òur study describes early experiences
from establishing CHB care and treatment in a resource-
limited setting, and we believe our findings can inform
national and international efforts to scale up treatment
globally.
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